Clinical Trials

72 enrolled 14 charts

Melanoma

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

BreastCNSDermatologicOther hematologic neoplasmThoracic

Melanoma

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase 1/2 Terminated

8 enrolled 13 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT06221397 2026-03-16

LEGIT_MC_EVCDA

Completed

105 enrolled 15 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Disease, Melanoma

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT04221438 2026-03-12

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase 2 Terminated

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

921 enrolled 48 charts 1 FDA

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Melanoma

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

1 enrolled

Melanoma

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT04526730 2026-02-20

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

17 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT04913220 2026-02-04

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Phase 1/2 Terminated

46 enrolled 22 charts

Phase 1/2 Active not recruiting

Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04157517 2026-01-29

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

45 enrolled 44 charts

Melanoma, Neoplasms

NCT02656706 2026-01-16

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

22 enrolled 10 charts

Melanoma

NCT03028948 2026-01-14

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Phase NA Completed

485 enrolled 22 charts

Melanoma

NCT02975700 2026-01-13

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Phase NA Completed

6 enrolled 21 charts

Melanoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04526899 2026-01-08

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

184 enrolled 11 charts

Melanoma

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT01004952 2026-01-07

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Completed

94 enrolled 8 charts

Phase 1 Active not recruiting

Melanoma

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT01970358 2025-12-29

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Phase 1 Completed

15 enrolled 8 charts

Melanoma

NCT00539591 2025-12-23

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

29 enrolled 28 charts

Melanoma

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts